Healthcare - Biotechnology - NASDAQ - US
$ 17.72
-4.06 %
$ 1.52 B
Market Cap
-3.92
P/E
CASH FLOW STATEMENT
-280 M
OPERATING CASH FLOW
55.8 M
INVESTING CASH FLOW
219 M
FINANCING CASH FLOW
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Travere Therapeutics, Inc.
| Net Income | -376 M |
| Depreciation & Amortization | 38.5 M |
| Capital Expenditures | -668 K |
| Stock-Based Compensation | 44.2 M |
| Change in Working Capital | -25.5 M |
| Others | 39.5 M |
| Free Cash Flow | -322 M |
Cash Flow
Millions
| Dec-2023 | Dec-2022 | Dec-2021 | Dec-2020 | Dec-2019 | Dec-2018 | Dec-2017 | Dec-2016 | Dec-2015 | Dec-2014 | Dec-2013 | Dec-2012 | Feb-2012 | Feb-2011 | Feb-2010 | Feb-2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| OPERATING CASH FLOW | ||||||||||||||||
| Net Income | (376.3) | (278.5) | (180.1) | (169.4) | (146.4) | (102.7) | (59.7) | (47.9) | 117.2 | (110.9) | (33.8) | (30.3) | 14.8 K | 23 K | 28 K | 18.3 K |
| Depreciation & Amortization | 38.5 | 33.1 | 26.6 | 24.6 | 20.4 | 18.7 | 17.8 | 16.1 | 13.4 | 5.4 | 0.2 | 0.1 | 0 | 8.33 K | 12.5 K | 0 |
| Deferred Income Tax | 0 | 0 | 4.1 | 2.0 | 41.3 | 20.3 | (6.4) | (22.7) | (15.6) | (2.5) | 75.8 K | 0 | 0 | 0 | 0 | 0 |
| Stock Based Compensation | 44.2 | 38.1 | 29.6 | 23.6 | 21.1 | 19.8 | 26.9 | 29.1 | 25.9 | 15.9 | 1.4 | 17.6 | 0 | 0 | 0 | 0 |
| Other Operating Activities | 39.0 | 19.0 | 23.8 | 102.5 | 2.7 | 7.9 | 25.1 | 18.3 | (130.1) | 33.9 | 13.0 | 6.8 | 12.8 K | 12 K | 2 K | 18.3 K |
| Change in Working Capital | (25.5) | 0.9 | 80.0 | (26.0) | 2.7 | 11.1 | 3.8 | 5.5 | (11.4) | 12.3 | 1.5 | 3.1 | 2 K | 2 K | 2 K | 19.5 K |
| Cash From Operations | (280.0) | (186.3) | (14.8) | (42.7) | (58.2) | (25.0) | 7.4 | (1.6) | (0.6) | (45.8) | (17.6) | (2.7) | 49 | 689 | 15.5 K | 18.3 K |
| INVESTING CASH FLOW | ||||||||||||||||
| Capital Expenditures | (0.7) | (28.6) | (24.2) | (119.8) | (15.6) | (19.7) | (14.0) | (11.9) | (7.0) | (4.0) | (5.5) | (1.2) | 0 | 0 | 0 | 0 |
| Other Items | 56.4 | (4.0) | (113.5) | 58.5 | 35.4 | (183.6) | 59.6 | 22.3 | (73.6) | (33.3) | 0.1 | (0.5) | 0 | 0 | 0 | 0 |
| Cash From Investing Activities | 55.8 | (32.6) | (137.6) | (61.3) | 19.9 | (203.3) | 45.6 | 10.4 | (80.6) | (37.3) | (5.4) | (1.7) | 0 | 0 | 0 | 0 |
| FINANCING CASH FLOW | ||||||||||||||||
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | (2.3) | (1.0) | 0 | 0 | 0 | 0 | 0 |
| Total Debt Repaid | 0 | 95.0 | 0 | 0 | 0 | 235.8 | 0 | 0 | (45.0) | 54.0 | (0.9) | 0.9 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 27.6 | 3.0 | 6.7 | (3.8) | (2.1) | (3.9) | 5.4 | (5.7) | (2.9) | 3.6 | (0.1) | 77.2 K | 0 | 0 | 0 | 25 K |
| Cash From Financing Activities | 218.8 | 117.6 | 231.7 | 127.7 | (2.1) | 231.9 | 5.4 | (5.7) | 100.8 | 95.3 | 29.0 | 4.4 | 0 | 0 | 0 | 25 K |
| CHANGE IN CASH | ||||||||||||||||
| Net Change In Cash | (3.5) | (104.1) | 81.0 | 22.3 | (40.4) | 3.5 | 58.4 | 3.2 | 19.6 | 12.2 | 6.0 | 1.34 K | 49 | 689 | 124 | 6.73 K |
| FREE CASH FLOW | ||||||||||||||||
| Free Cash Flow | (322.3) | (214.8) | (38.9) | (162.6) | (73.8) | (44.7) | (6.6) | (13.5) | (7.6) | (49.8) | (23.1) | (3.9) | 49 | 689 | 15.5 K | 18.3 K |